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Purpose: Concurrent chemoradiotherapy has become the standard 
treatment for unresectable locally advanced non-small cell lung cancer 
(NSCLC). However, distant metastases remain the major site of failure. 
Here we report a randomized phase II trial of consolidation chemother-
apy with monthly paclitaxel and cisplatin (PC) or observation after con-
current chemoradiotherapy in patients with locally advanced NSCLC to 
evaluate the feasibility and the role of consolidation chemotherapy.
Methods: Between March 2000 and August 2002, a total of 104 
unresectable stage III NSCLC patients who showed at least minimal 
response (6 complete, 86 partial, and 12 minimal responses) after 
concurrent chemoradiotherapy were randomized to receive 3 cycles of 
consolidation chemotherapy (n=50) or to be observed (n=54). Con-
current chemoradiotherapy consisted of weekly paclitaxel 40 mg/m2 
and cisplatin 20 mg/m2 plus thoracic radiation (total dose of 70.2 Gy). 
Consolidation chemotherapy with paclitaxel 135 mg/m2 and cisplatin 
60 mg/m2 started 4 weeks after completion of concurrent chemoradio-
therapy and repeated every 4 weeks. 
Results: With a median follow-up of 41 months, there were no signiﬁ-
cant differences in progression-free survival (PFS) and overall survival 
(OS) between consolidation and observation groups (median PFS, 13 
vs. 12 months; median OS, 19 vs. 24 months). During consolidation 
PC, grade 3 or 4 neutropenia was observed in 29% of the patients. 
However, there was no episode of febrile neutropenia. 
Conclusions: Consolidation chemotherapy with monthly PC after con-
current chemoradiotherapy is feasible and generally tolerable, however, 
does not show a survival beneﬁt in locally advanced
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Background: Some papers report that tumor volume is a signiﬁcant 
prognostic factor in thoracic radiotherapy for non-small-cell lung can-
cer (NSCLC) patients. The purpose of this study is to investigate and 
conﬁrm the impact of total tumor volume(TTV) on survival in patients 
with stage III NSCLC treated with thoracic radiotherapy and concur-
rent chemotherapy.
Methods: From prospectively maintained database of our department, 
sixty patients were identiﬁed who underwent thoracic radiotherapy 
and concurrent chemotherapy in stage III NSCLC patients with an age 
under 75 year between October 2002 and December 2005. All patients 
underwent a CT scanning to facilitate treatment planning. TTV were 
calculated by the three-dimensional radiotherapy planning system. The 
median follow-up duration was 21 months in surviving patients. The 
Kaplan-Meier method, the log rank test and the Cox proportional haz-
ard model were used for evaluation of survival. Survival was updated 
on March 1,2007.
Results: The patients consisted of 47 males and 13 females in gender, 
64 year old of median age (range 44-75), 27 IIIA and 33 IIIB in TNM 
staging, 24 squamous cell carcinoma, 30 adenocarcinoma and 6 oth-
ers in histology and 39 PS 0, 19 PS1, 2 PS2 in performance status, 
respectively. TTV was ranged between 11 and 1512 cc (median 78.5 
cc). A prescribed dose of radiotherapy was 60 Gy in 30 fractions using 
4-,6- or 10-MV X-rays in all patients. Chemotherapy regimens were 
as follows: 1) weekly paclitaxel (TXL)+ weekly carboplatin(CBDCA) 
consolidation CBDCA + TXLx2 in 33 patients, 2) mitomycin C + vin-
desine+ cisplatin x 4 in 12, 3)cisplatin+vinorelbinex4 in 8 and 4)others 
in 7. The overall 2-year survival rate was 66 %. In patients with larger 
TTV than median TTV 78.5 cc and with smaller TTV, the overall 2-
year survival rates were 52% and 80%, respectively. The median over-
all survival was 29 months. The median overall survival with smaller 
TTV is not mature enough to be evaluated. On univariate analysis, 
stage IIIA was signiﬁcantly better prognostic factor than IIIB (P=0.042) 
and the survival with smaller TTV tends to be favorable (P=0.056). PS 
(P=0.908) and gender (P=0.356) were not signiﬁcant. On multivari-
ate analysis, there was tendency of favorable survival in smaller TTV 
(P=0.068) and others (stage, PS, gender) were not signiﬁcant.
Conclusion: TTV is an independent prognostic factor in stage III 
NSCLC treated with concurrent chemoradiotherapy.
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Background: The optimal duration of chemotherapy for advanced 
non-small cell lung cancer (NSCLC) is unclear. We performed a sys-
tematic review and meta-analysis of published randomized controlled 
trials (RCT) comparing longer versus shorter durations of chemo-
therapy. 
Methods: We searched MEDLINE, EMBASE and CENTRAL for 
RCTs comparing 1) a deﬁned number of cycles of chemotherapy versus 
continuing until disease progression, 2) a deﬁned number of cycles 
versus a higher number of cycles of the same chemotherapy and, 3) a 
deﬁned number of cycles of initial chemotherapy vs the same initial 
chemotherapy followed by additional cycles of a different chemo-
therapy. The primary outcome was overall survival (OS). Secondary 
outcomes included progression-free survival (PFS), adverse events 
(AE), and quality of life (QL). Hazard ratios (HR), conﬁdence intervals 
(CI) and p-values (p) were estimated with ﬁxed effects models using 
Revman 4.2.8
